Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/23/2013)... May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... technology company, today scheduled a conference call to discuss ... year 2013, ended April 30, 2013. The call will ... 2013. The Company will report financial results for the ... close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... 23, 2013 More than half of women ... from chemotherapy and still have excellent outcomes. To educate ... of the largest sources of online consumer information about ... Facebook page provide recently diagnosed women with information sources, ... chemotherapy. "We anticipate these innovative social media ...
(Date:5/23/2013)... May 23, 2013  Texas, premier physician associations today ... the survival tools they need to provide demonstrably better ... health care marketplace. "I am confident the ... practices," said Stephen L. Brotherton , ... Texas doctors are determined to make ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
(Date:5/24/2013)... 24, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html ... latest update involving allegations that the use of ... can allegedly cause potentially fatal irregular heart ... May 17, 2013* that Health Canada has joined ... that Zithromax can cause abnormal changes in the ...
(Date:5/24/2013)... May 24, 2013 Scott Ryan Tischler ... Troy Tischler, lose 200 lbs. of fat in just ... teach his younger brother the importance of exercising. Scott ... By sticking to these 7 rules of healthy eating ... goals can be accomplished. , 1.    Find a distraction when ...
(Date:5/24/2013)... 2013 Psoriasis treatment cream has been ... This new FDA registered company is now offering its ... appearance of Psoriasis infected skin. , Dermasis has launched ... online. This soothing cream is designed to offer immediate ... and appearance of red skin often caused by psoriasis ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 ... the Cellulite Whisperer line, with a ... for Summer Sale" includes two proprietary products, the ... Whisperer® Lotion . , Purchasers receive a report ... , "The Gel has a wonderful grapefruit scent," ...
(Date:5/23/2013)... Plantation, FL (PRWEB) May 24, 2013 ... and coaching educators in tennis for over 29 years, ... more than 50 ATP & WTA players, Grand Slam ... and Italian Open Champions, 25 USTA National Junior Champions, ... ITF Junior Champions, including Sunshine Cup, Orange Bowl and ...
Breaking Medicine News(10 mins):Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4Health News:Dermasis Psoriasis Treatment Cream for Men and Women Released Online at HealthCareSupplementz.com 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2
... -- A study in the December issue of the ... why death rates for less educated middle aged adults are ... awareness and treatments aimed at reducing health disparities. For ... education levelsthat is high school or lessare twice as likely ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) -- Every ... rape, physical violence, or stalking by an intimate partner, according ... to data from the U.S. Centers for Disease Control and ... of partner violence each year, with by far the biggest ...
... ,Headache affects 50 percent of HIV/AIDS patients in the United ... study says. About 27.5 percent of the 200 HIV/AIDS ... in which a person has migraine symptoms (with or without ... condition occurs in only 2 percent of the general population. ...
... diagnosed with locally-advanced pancreatic cancer in the United States ... these patients whose tumor has grown beyond the pancreas ... years, numerous treatment regimens have been evaluated for locally-advanced ... the current standard approach. However, the median survival time ...
... developing countries rely on traditional medicine as an accessible ... now, scientific data has not existed to evaluate the ... from the William L. Brown Center of the Missouri ... brine shrimp to determine the toxicity of 341 Northern ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Dec. ... that prevents them from sensing or reacting to anything ... a plate or recognizing a person sitting to that side ... cells in their brain, Italian researchers report. This inability ...
Cached Medicine News:Health News:Study takes aim at education-based death rate disparities 2Health News:Millions of Americans Are Victims of Sexual Violence: CDC 2Health News:Millions of Americans Are Victims of Sexual Violence: CDC 3Health News:Headaches May Plague Many With HIV/AIDS 2Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Missouri Botanical Garden scientists examine toxicity of medicinal plants in Peru 2Health News:Missouri Botanical Garden scientists examine toxicity of medicinal plants in Peru 3Health News:Magnetic Brain Stimulation Might Help Some Stroke Patients 2Health News:Magnetic Brain Stimulation Might Help Some Stroke Patients 3
... The Anti-HCV Low Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... Comprehensive data from all major test systems ...
... Panel consists of plasma specimens with reactivity ... antibodies to the Hepatitis C Virus., This ... manufacturers and clinical laboratories to evaluate their ... all major test systems are included for ...
... POPmesh is a ... that can be used ... pelvic floor procedures, including ... prolapse. Supple yet strong, ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
Medicine Products: